Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and - negative women

L. Wideroff, M. H. Schiffman, R. Hoover, R. E. Tarone, B. Nonnenmacher, N. Hubbert, R. Kirnbauer, C. E. Greer, A. T. Lorincz, M. M. Manos, A. G. Glass, D. R. Scott, M. E. Sherman, J. Buckland, D. Lowy, J. Schiller

Research output: Contribution to journalArticlepeer-review

63 Scopus citations

Abstract

The epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 L1/L2 virus-like particles (VLPs) were assessed separately in HPV-16 DNA-positive and -negative women participating in a nested case- control study of incident cervical neoplasia. Seventy-four women with cervical HPV-16 DNA and 656 cytologically normal HPV-16 DNA-negative subjects were interviewed and tested at two time points for viral DNA and once (at the later time) for VLP seroreactivity. Among subjects who were currently HPV-16 DNA-negative, seroreactivity odds ratios increased from 2.9 for 2-5 male sex partners (vs. 0 or 1) to 5.4 for 6-9 partners and 14.0 for ≤10. Thus, prior cervical infection may be a major determinant of seroreactivity in HPV-16 DNA-negative women. This trend was not observed in HPV-16 DNA-positive subjects. Seroreactivity was independently associated with oral contraceptive use, particularly in HPV-16 DNA-negative subjects with use for ≤10 years. Consequently, a possible role for virus-steroid hormone interactions in seroconversion is suggested.

Original languageEnglish (US)
Pages (from-to)937-943
Number of pages7
JournalJournal of Infectious Diseases
Volume174
Issue number5
DOIs
StatePublished - 1996

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and - negative women'. Together they form a unique fingerprint.

Cite this